Krystal Biotech Inc KRYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $307.79
- Day Range
- $300.02–312.81
- 52-Week Range
- $127.99–319.48
- Bid/Ask
- $301.00 / $324.00
- Shares Outstanding
- 29.48M
- Market Cap
- $8.87B
- Volume/Avg
- 264,455 / 270,758
Key Statistics
- Price/Earnings (Normalized)
- 40.85
- Price/Sales
- 21.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 295
- Website
- https://www.krystalbio.com
Valuation
|
Metric
|
KRYS
|
|---|---|
Price/Earnings (Normalized) | 40.85 |
Price/Book Value | 6.93 |
Price/Sales | 21.70 |
Price/Cash Flow | 35.09 |
Price/Earnings
KRYS
Financial Strength
|
Metric
|
KRYS
|
|---|---|
Quick Ratio | 8.82 |
Current Ratio | 9.46 |
Interest Coverage | — |
Quick Ratio
KRYS
Profitability
|
Metric
|
KRYS
|
|---|---|
Return on Assets (Normalized) | 21.37% |
Return on Equity (Normalized) | 23.35% |
Return on Invested Capital (Normalized) | 21.17% |
Return on Assets
KRYS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hxmblpl | Xtfxgs | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vqwbtqc | Gfvhhc | $67B | |||
| argenx SE ADR
ARGX
| Mvwpwmxtm | Ghx | $53B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gnjvnhwqm | Gsghrcl | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Rsmhpfrfft | Vqwpzq | $25B | |||
| BioNTech SE ADR
BNTX
| Zvqkhbnr | Bttp | $22B | |||
| Incyte Corp
INCY
| Zmtxwjsn | Xgvn | $20B | |||
| Moderna Inc
MRNA
| Skmdlvkkf | Dyj | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tsvcssjs | Kcg | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Yztszfqg | Mqpjf | $13B |
United States